Comparative Pharmacology
Head-to-head clinical analysis: OXAPROZIN versus TAB PROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXAPROZIN versus TAB PROFEN.
OXAPROZIN vs TAB-PROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which results in anti-inflammatory, analgesic, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor; reduces prostaglandin synthesis.
600-1200 mg orally once daily; maximum 1800 mg/day.
400-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 50–60 hours in healthy adults; clinical context: once-daily dosing achieves steady-state in 7–10 days.
Clinical Note
moderateOxaprozin + Gatifloxacin
"Oxaprozin may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateOxaprozin + Rosoxacin
"Oxaprozin may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateOxaprozin + Levofloxacin
"Oxaprozin may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateOxaprozin + Trovafloxacin
"Oxaprozin may increase the neuroexcitatory activities of Trovafloxacin."
The terminal elimination half-life is 2-4 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Primarily hepatic metabolism (glucuronidation and hydroxylation) with renal excretion of metabolites; less than 1% excreted unchanged in urine; fecal elimination accounts for ~20%.
Renal excretion of unchanged drug accounts for approximately 70-90% of the administered dose, with the remainder eliminated as glucuronide conjugates in urine. Biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
NSAID
NSAID